14.96 USD
▼-0.97-6.09%
盘后 15.00 +0.27%
2026-09-15
市值
$999.46M
市盈率
—
EPS
-0.56
股息率
—
52 周区间
0.88 – 17.25
成交量
171.30K
Beta
1.10
目标价
29.50
52W 低 0.8852W 高 17.25
价格走势
公司简介
Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors. Its immunotherapy programs include AN8025, a tri-functional fusion protein (αPD-L1 x CD86 variant x LAG3 variant) t...